Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | FASN | P49327 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | RHEB | Q15382 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528932 | 0.91 | KDM4E (0.59) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3748314 | 0.87 | EGFR (0.48) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2037708 | 0.86 | SRD5A2 (0.59) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29788004 | 0.86 | SRD5A2 (0.59) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3753642 | 0.86 | ERN1 (0.51) | CA1CA2EGFRMAPTRHEB | |
| SCHEMBL3743373 | 0.86 | CYP2C9 (0.47) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4300304 | 0.84 | SRD5A2 (0.60) | EGFRKMT2ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL12836646 | 0.83 | CA1 (0.61) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL497995 | 0.83 | HSD17B1 (0.58) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL497642 | 0.83 | CA1 (0.61) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | VIB VZW (BE) | 2025-04-10 | — | — | US | disclosed |
| EP-4452253-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | The Katholieke Universiteit Leuven (BE) | 2024-10-30 | — | — | EP | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDM4E 516/4885CYP1A2 2621/4885CYP2D6 3797/4885 |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDM4E 1163/4885CYP1A2 2997/4885CYP2D6 4269/4885 |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | KDM4E 2042/4885CYP1A2 1288/4885CYP2D6 1651/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDM4E 1163/4885CYP1A2 2997/4885CYP2D6 4269/4885 |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDM4E 1163/4885CYP1A2 2997/4885CYP2D6 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.